The Department of Health and Human Services (HHS) is preparing a significant structural overhaul at the Food and Drug Administration (FDA) by establishing two new deputy commissioner positions. These newly created roles will focus specifically on technology—particularly the integration of artificial intelligence in healthcare—and pharmaceutical drugs. The positions are designed to report directly to Heidi Overton, President Donald Trump’s nominee for FDA commissioner, who is currently awaiting Senate confirmation.

The proposed technology deputy commissioner will be tasked with a dual mandate: managing the FDA’s internal adoption of artificial intelligence tools and overseeing the regulatory review process for AI-enabled medical devices. Jared Seehafer, a veteran of the medical device industry and current senior advisor to the FDA, has emerged as the frontrunner for this technology-focused position. Seehafer previously co-founded the life sciences compliance software firm Enzyme. Meanwhile, the administration has yet to name a leading candidate for the newly proposed deputy commissioner for drugs.

This leadership restructuring comes during a highly challenging period for the FDA, marked by intense public and political scrutiny. The agency has recently faced criticism over its response to a multistate cyclospora outbreak linked to iceberg lettuce, amid concerns that budget and staffing constraints are weakening food safety oversight. Additionally, the FDA has navigated several high-profile and controversial drug regulatory battles, including the accelerated approval of Replimune’s melanoma drug Tudriqev and a reversed stance on clinical trial requirements for UniQure’s experimental Huntington’s disease treatment.

The creation of a dedicated technology role aligns with the FDA’s growing reliance on artificial intelligence. The agency already utilizes an internal generative AI tool called Elsa for document summarization and drafting, while simultaneously facing the complex task of regulating external AI medical products. The FDA recently published a discussion paper seeking stakeholder feedback on regulating generative AI-enabled medical devices, signaling a shift toward collaborative oversight. Observers note that the introduction of these new deputy roles could allow the administration to exert greater policy influence over the regulatory body.

Key Takeaways

• HHS is planning to establish two new FDA deputy commissioner roles focusing on technology/AI and pharmaceutical drugs.
• Jared Seehafer, a medical device industry veteran and current FDA advisor, is the leading candidate to head the new technology division.
• The restructuring aims to streamline the regulation of AI-enabled medical devices and internal AI tools, while potentially increasing administration influence over the agency.

Editor’s Analysis & Impact

The creation of dedicated deputy commissioner roles for technology and drugs represents a pivotal shift in how the FDA intends to navigate the rapidly evolving landscape of modern medicine. By placing a specific emphasis on artificial intelligence, the agency acknowledges that AI is no longer a futuristic concept but a current regulatory challenge. This structural change will likely accelerate the approval pathways for AI-driven medical devices and software, providing much-needed clarity to biotech and health-tech developers. However, the move also signals a desire by the executive branch to exert tighter control over an agency that has recently faced public friction over food safety and controversial drug approvals. For the pharmaceutical and tech industries, this reorganization could mean more specialized oversight, but it also introduces potential political volatility into the regulatory approval pipeline.

Frequently Asked Questions

Q: What are the responsibilities of the proposed FDA deputy commissioner for technology?
A: The role will oversee both the FDA's internal implementation of artificial intelligence tools, such as its document-summarizing tool Elsa, and the regulatory evaluation of AI-enabled medical devices entering the market.

Q: Who will these new deputy commissioners report to?
A: Both new positions are structured to report directly to the FDA Commissioner. Currently, President Trump's nominee for the commissioner role is Heidi Overton, who is awaiting Senate confirmation.

Q: Why is the FDA creating these new positions now?
A: The restructuring comes amid growing pressure on the FDA regarding its handling of foodborne illness outbreaks and complex drug approvals, as well as the urgent need to establish clear regulatory frameworks for generative AI in healthcare.